Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy

Nephrology Dialysis Transplantation

Volumn 16, Issue 12, 2001, Pages 2289-2293

  Itri, Loretta M ^a  

^a Genta Incorporated   (United States)

Author keywords

Anaemia; Epoetin alfa

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HUMAN; MEDICAL SPECIALIST; NEPHROLOGY; ONCOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0035210976     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.12.2289     Document Type: Editorial

References (30)

1. Anemia of end-stage renal disease (ESRD)
2. Anemia in cancer patients
3. Mechanisms of anaemia in patients with malignancy: Implications for the clinical use of recombinant human erythropoietin
4. Decreased erythropoietin response in patients with the anemia of cancer
5. Serum erythropoietin level in anemic cancer patients
6. Proinflammatory cytokines lowering erythropoietin production
7. Anemia
8. Chemotherapy-induced anemia in adults: Incidence and treatment
9. Patient, caregiver and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey
10. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition
11. Symptom and quality of life survey of medical oncology patients at a Veterans Affairs medical center: A role for symptom assessment
12. Comparison of changes in physical functioning of elderly patients with new diagnoses of cancer
13. Erythropoietin for anaemia in cancer patients
14. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo
15. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
16. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies
17. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
18. Recombinant human erythropoietin for the correction of cancer associated with anemia with and without concomitant cytotoxic chemotherapy
19. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
20. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
21. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
22. The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem
23. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
24. K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000
25. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated postsurgical setting: The importance of iron availability in optimizing response
26. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery
27. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects
28. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life similar to three-times-weekly dosing
29. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy
30. Quality of life and anemia: The nephrology experience